

12th ESUR Prostate MRI

Hotel Theater Figi | Zeist, The Netherlands | 27 - 29 June, 2024



ONLINE PROGRAMME





08:00 – 09:00 REGISTRATION, COFFEE

08:45 – 08:50 WELCOME
Jelle. O. Barentsz, Nijmegen - Ivo Schoots, Rotterdam

08:50 – 09:40 PROSTATE MRI IN DIAGNOSIS
Jelle. O. Barentsz, Nijmegen - Geert Villeirs, Ghent

Prostate histology and pathology: What is “significant” prostate cancer?	Arno van Leenders, Rotterdam
Prostate MRI: What abnormalities can we expect to see?	Geert Villeirs, Gent
PI-RADS v2.1: How do we classify prostate abnormalities?	Jelle Barentsz, Nijmegen
Discussion	

09:40 – 10:30 MRI CHALLENGES: BENEFIT/HARMS, ACQUISITION, AND QUALITY
Tristan Barrett, Cambridge - Ivo Schoots, Rotterdam

MRI-pathway: What are de benefits and harms?	Ivo Schoots, Rotterdam
MRI quality: How do we acquire a high-quality scan? fast MRI – can we speed up acquisition?	Tom Scheenen, Nijmegen
MRI quality: What is PI-QUAL v1.0 and v2.0 classification? Why is it necessary? How can we assure quality in daily practice?	Tristan Barrett, Cambridge
Discussion	

10:30 – 11:00 COFFEE/TEA BREAK

11:00 – 11:50 MRI CHALLENGES: CONTRAST, PI-RADS 3, INTEROBSERVER VARAIBILITY, ADC QUANTIFICATION
Jonathan Richenberg, Brighton - Tom Scheenen, Nijmegen

MRI and contrast: When do we need contrast?	Jonathan Richenberg, Brighton
MRI and interobserver variability: Why and how can we reduce false positives?	Raphaelle Renard-Penna, Paris
MRI and PI-RADS 3 cases: How can we reduce indeterminate cases?	Ivo Schoots, Rotterdam
MRI: What are the challenges in ADC metric quantification?	Tom Scheenen, Nijmegen
Discussion	

11:50 – 12:40 MRI CHALLENGES: RISK ASSESSMENT, BIOPSY, HISTOLOGY ANALYSIS
Philippe Puech, Lille - Olivier Rouviere, Lyon

Pre-biopsy risk: How can we use MRI in risk assessment?	Roderick van de Bergh, Rotterdam
Biopsy approach: How can we use MRI in guiding biopsy strategy Cognitive, fusion, or in-bore biopsy?	Philippe Puech, Lille
Biopsy challenges: How can we reduce false negatives?	Olivier Rouviere, Lyon
Biopsy analyses: How do we use aggregated scoring?	Arno van Leenders, Rotterdam

12:40 – 13:40 INDUSTRY LUNCH SYMPOSIUM

PARALLEL SESSION / WORKSHOPS

15:45 – 16:15 COFFEE/TEA BREAK

16:15 – 17:05 MRI IN ACTIVE SURVEILLANCE
Francesco Giganti, London - Pim van Leeuwen, Amsterdam

Surveillance: What are the indications, adoption, and risk assessment?	Francesco Sanguedolce, Barcelona
Surveillance: How do we use PRECISE v1.0 in monitoring and guiding patient management?	Raphaelle Renard-Penna, Paris
Surveillance: Are we ready for MRI-based active monitoring (no/delayed biopsy)?	Pim van Leeuwen, Amsterdam
PRECISE international collaboration: What are the results of v1.0 international study and consensus meeting v2.0?	Francesco Giganti, London
Discussion	

17:05 – 17:15 SUMMARY AND CLOSING
Jelle Barentsz, Nijmegen - Ivo Schoots, Rotterdam

13:40 – 14:40

PARALLEL SESSION / WORKSHOPS

SESSION 1

ROOM 1: COPIJNZAAL RW 1A	Radiological workshop – Prostate MRI: cases (5-10) on PI-RADS assessment	Vibeke Logager, Copenhagen Andrea Ponsiglione, Napels
ROOM 2: SPRINGERZAAL RW 2A	Radiological workshop – Prostate MRI: cases (5-10) on notorious pitfalls and tricks	Kai (JC) Vilanova, Girona Martina Pecoraro, Rome
ROOM 3: ZOCHERZAAL HOT 1	Hands-on training (a) (24 people)	Marloes van der Leest, Nijmegen Ailin Dehganpour, Rome
ROOM 4: TERSTEEGZAAL HOT 2	Hands-on training (b) (24 people)	Patrick Zamecnik, Nijmegen George Agrotis, Larissa
ROOM 5: WILLEM PIJPERZAAL MDT 1A	Multi-disciplinary (MDT) team workshop – MRI and biopsy: Case-discussion on risk stratification and biopsy decision	Olivier Rouviere, Lyon Roderick van de Bergh, Rotterdam Francesco Sanguedolce, Barcelona Floris Pos, Amsterdam Arno van Leenders, Rotterdam
ROOM 6: JOHAN DE MEERSTERZAAL RW 3A	Radiological workshop – MRI quality: cases (5-10) on PI-QUAL in daily practice	Tristan Barrett, Cambridge Maarten de Rooij, Nijmegen
ROOM 7: HANS KAZÀNZAAL RW 4A	Radiological case-based workshop – MRI challenges: cases on indeterminate scans	Geert Villeirs, Gent Joe Busch, USA

14:40 – 14:45

CHANGE ROOMS

14:45 – 15:45

PARALLEL SESSION / WORKSHOPS

SESSION 2

ROOM 1: COPIJNZAAL RW 1B	Radiological workshop – Prostate MRI: cases (5-10) on PI-RADS assessment	Vibeke Logager, Copenhagen Andrea Ponsiglione, Napels
ROOM 2: SPRINGERZAAL RW 2B	Radiological workshop – Prostate MRI: cases (5-10) on notorious pitfalls and tricks	Kai (JC) Vilanova, Girona Martina Pecoraro, Rome
ROOM 3: ZOCHERZAAL HOT 3	Hands-on training (a) (24 people)	Marloes van der Leest, Nijmegen Ailin Dehganpour, Rome
ROOM 4: TERSTEEGZAAL HOT 4	Hands-on training (b) (24 people)	Patrick Zamecnik, Nijmegen George Agrotis, Larissa
ROOM 5: WILLEM PIJPERZAAL MDT 1B	Multi-disciplinary (MDT) team workshop – MRI and biopsy: Case-discussion on risk stratification and biopsy decision	Olivier Rouviere, Lyon Roderick van de Bergh, Rotterdam Francesco Sanguedolce, Barcelona Floris Pos, Amsterdam Arno van Leenders, Rotterdam
ROOM 6: JOHAN DE MEERSTERZAAL RW 3B	Radiological workshop – MRI quality: cases (5-10) on PI-QUAL in daily practice	Tristan Barrett, Cambridge Maarten de Rooij, Nijmegen
ROOM 7: HANS KAZÀNZAAL RW 4B	Radiological case-based workshop – MRI challenges: cases on indeterminate scans	Geert Villeirs, Gent Joe Busch, USA



08:00 – 09:00 REGISTRATION, COFFEE

08:30 – 08:35 WELCOME
Jelle. O. Barentsz, Nijmegen - Ivo Schoots, Rotterdam

08:35 – 09:25 IMAGING IN LOCALLY ADVANCED PROSTATE CANCER: T-STAGING AND TREATMENT DECISIONS

Geert Villiers, Gent - Henk van der Poel, Amsterdam

MRI and T-staging: How and why should we report?	Geert Villeirs, Gent
PSMA PET-CT in T-staging: How good are we? What are indiications?	Lisa Tarlinton, Sydney
Is there a role for PSMA PET/MRI?	
MRI, T-staging, and risk models: how can we identify increased risk of T3 and N/M disease for treatment decisions?	Henk van der Poel, Amsterdam
MRI and imaging-guided radiation: What is GTV, CTV, and PTV? what are the advantages of MR-Linac (T3)? Is focal boosting ready for Prime-Time?	Uulke van de Heide, Amsterdam
Discussion	

09:25 – 10:25 IMAGING IN LOCALLY ADVANCED PROSTATE CANCER: N/M-STAGING AND TREATMENT DECISIONS

Giueseppe Petralia, Milan - James Nagarajah, Dusseldorf

N/M-staging: what information do we need for treatment decisions: ePLND, pelvic IMRT, ADT?	Pim van Leeuwen, Amsterdam
MRI whole-body and N/M-staging: What is the added value and what are the key issues?	Giueseppe Petralia, Milan
MRI USPIO contrast and N-staging by: What are the indications for this next generation imaging modality?	Patrik Zamecnik, Nijmegen
PSMA PET-CT and N/M-staging: what are the indications? benefits for treatment decision? Theranostics?	Lisa Tarlinton, Sydney
Theranostics in prostate cancer, bridging diagnostics with treatment – what are the indications and how to organize/approach?	James Nagarajah, Dusseldorf
Discussion	

10:25 – 11:00 COFFEE/TEA BREAK

PARALLEL SESSION / WORKSHOPS

13:05 – 14:00 INDUSTRY LUNCH SYMPOSIUM

14:00 – 14:50 BIOCHEMICAL RECURRENCE IN PROSTATE CANCER

Valeria Panebianco, Rome - Jurgen Futterer, Nijmegen

BCR and PSA persistence: what are the criteria, what is the diagnostic and monitoring work-up? salvage treatment options?	Tobias Maurer, Hamburg
BCR and MR: What is structured reporting following PI-RR?	Valeria Panebianco, Rome
BCR and PSMA-PET: What are the changes in treatment decisions?	Lisa Tarlinton, Sydney
Imaging post focal treatment: how should we interpret?	Jurgen Futterer, Nijmegen
Discussion	

14:50 – 16:00 AI/CAD SOFTWARE IN PROSTATE CANCER DIAGNOSIS

Anwar Padhani, London - Derya Yakar, Groningen

AI: What are the essentials/basics in AI/CAD tools in MRI assessment?	Renato Cuocolo, Salerno
AI: What are the current CE-marked AI/CAD tools in MRI assessment?	Industry pitches on prostate MRI/CAD systems
AI: What are the challenges regarding tools variability, generalizabilty and, necessary validation?	Derya Yakar, Groningen
AI: What are the challenges regarding target population, cancer prevalence, and diagnostic performance?	Tobias Penzkofer, Berlin
AI: What do you need to think before you buy?	Anwar Padhani, London
Discussion	

16:00 – 16:30 COFFEE/TEA BREAK

16:30 – 17:20 AI PERSPECTIVES FROM DEVELOPMENT TO IMPLEMENTATION

Jonathan Richenbourg, Brighton - Maarten de Rooij, Nijmegen

AI: industries challenges: How to coop with constantly improving, and commercial, ethical, and legal issues?	Jelle Barentsz, Nijmegen
AI: radiology perspectives: How does the future radiologist look like?	Derya Yakar, Groningen

AI: How should the radiological community guide AI companies?	Jonathan Richenburg, Brighton
AI: What are the assets and preliminary outcomes of the PICAI challenge initiative?	Maarten de Rooij, Nijmegen
Discussion	

17:20 – 17:30 SUMMARY AND CLOSING

Jelle Barentsz, Nijmegen - Ivo Schoots, Rotterdam

11:00 – 12:00**PARALLEL SESSION / WORKSHOPS****SESSION 3**

ROOM 1: COPIJNZAAL MDT 2A	Multi-disciplinary team workshop – Imaging and staging: cases on T-staging and treatment decision (surveillance / surgery)	Geert Villiers, Gent Lisa Tarlington, Sydney Henk van der Poel, Amsterdam
ROOM 2: SPRINGERZAAL MDT 3A	Multi-disciplinary team workshop – Imaging and staging: cases on N/M-staging and treatment decision (surgery/radiation/systemic treatment)	Giuseppe Petralia, Milan (chair) (rad) James Nagarajah, Dusseldorf (nuc) Pim van Leeuwen, Amsterdam (uro)
ROOM 3: ZOCHERZAAL HOT 5	Hands-on training (a) (24 people)	Sam Whitey, London Margriet van Dijk, Amsterdam
ROOM 4: TERSTEEGZAAL HOT 6	Hands-on training (b) (24 people)	Matthias Roethke, Heidelberg Thierry Boellaard, Amsterdam
ROOM 5: WILLEM PIJPERZAAL MDT 4A	Multi-disciplinary team workshop – Imaging and radiation: cases on indication, GTV/CTV, and focal boosting (radiation)	Floris Pos, Amsterdam Olivier Rouviere, Lyon Patrik Zamecnik, Nijmegen Harm van Melick, Utrecht Uulke van der heide, Amsterdam
ROOM 6: JOHAN DE MEERSTERZAAL RW 5A	Radiological case-based workshop – MRI in active surveillance: cases on PRECISE v2.0 assessment	Francesco Giganti, London Raphaelle Renard-Penna, Paris
ROOM 7: HANS KAZANZAAL RW 6A	Radiological case-based workshop – AI / CAD systems and MRI: cases on current vendors	Tobias Penzkofer, Berlin Jonathan Richenburg, Brighton Renato Cuocolo, Salerno

12:00 – 12:05**CHANGE ROOMS****12:05 – 13:05****PARALLEL SESSION / WORKSHOPS****SESSION 4**

ROOM 1: COPIJNZAAL MDT 2B	Multi-disciplinary team workshop – Imaging and staging: cases on T-staging and treatment decision (surveillance / surgery)	Geert Villiers, Gent Lisa Tarlington, Sydney Henk van der Poel, Amsterdam
ROOM 2: SPRINGERZAAL MDT 3B	Multi-disciplinary team workshop – Imaging and staging: cases on N/M-staging and treatment decision (surgery/radiation/systemic treatment)	Giuseppe Petralia, Milan James Nagarajah, Dusseldorf Pim van Leeuwen, Amsterdam
ROOM 3: ZOCHERZAAL HOT 7	Hands-on training (a) (24 people)	Sam Whitey, Brighton Margriet van Dijk, Amsterdam
ROOM 4: TERSTEEGZAAL HOT 8	Hands-on training (b) (24 people)	Thierry Boellaard, Amsterdam Matthias Roethke, Heidelberg
ROOM 5: WILLEM PIJPERZAAL MDT 4B	Multi-disciplinary team workshop – Imaging and radiation: cases on indication, GTV/CTV, and focal boosting (radiation)	Floris Pos, Amsterdam Patrik Zamecnik, Nijmegen Harm van Melick, Utrecht Uulke van der heide, Amsterdam
ROOM 6: JOHAN DE MEERSTERZAAL RW 5B	Radiological case-based workshop – MRI in active surveillance: cases on PRECISE v2.0 assessment	Francesco Giganti, London Raphaelle Renard-Penna, Paris
ROOM 7: HANS KAZANZAAL RW 6B	Radiological case-based workshop – AI / CAD systems and MRI: cases on current vendors	Tobias Penzkofer, Berlin Jonathan Richenburg, Brighton Renato Cuocolo, Salerno



08:00 – 09:00 **REGISTRATION, COFFEE**

08:45 – 08:50 **WELCOME**

Jelle. O. Barentsz, Nijmegen - Ivo Schoots, Rotterdam

08:50 – 09:40

BUILDING PROSTATE CANCER NETWORKS / UNITS

Chris Bangma, Rotterdam - Mara Blonden-Hidding, Amsterdam

Andros Clinics (NL): What are key business factors in high-volume cancer diagnosis?	Domien Debruyne, Andros, Arnhem
Center of Early Diagnosis (EU): How can we drive research in the field of early diagnosis? or how is healthcare on prevention medicine insured?	Mara Blonden-Hidding, Amsterdam
Martini Klinik Hamburg: Centralization of diagnostic care – What lessons can we learn from treatment?	Tobias Maurer, Hamburg
Prostate cancer networking in the Netherlands: What are the pros and cons of network medicine?	Chris Bangma, Rotterdam
Discussion	

09:45 – 10:35

CERTIFICATION AND ACCREDITATION IN PROSTATE CANCER DIAGNOSIS / SCREENING

Philippe Puech, Lille - Jeroen Veltman, Hengelo

Why is there a need for radiological certification and accreditation? What are the developments?	Philippe Puech, Lille
How can a digitized displaying tool on diagnosis and radiological workflow aid in accreditation and MDT's prostate cancer care?	Marco Jansen, Philips, Eindhoven
What lessons can we learn from breast cancer diagnostic/screening units on certification and accreditation regarding quality assessment?	Jeroen Veltman, Hengelo
Voluntary ESUR prostate MRI examination: A step towards certification?	Geert Villiers, Gent
Discussion	

10:35 – 11:00

COFFEE/TEA BREAK

11:00 – 11:50

PROSTATE CANCER SCREENING

Anwar Padhani, London - Hein van Poppel, Brussels

Prostate cancer screening: What is the patient perspective?	Erik Briers, UOMO, EAU guidelines
Prostate cancer screening: What are the European developments? (EU beating cancer plan, PRAISE-U)	Hein van Poppel, Brussels
Breast cancer screening: What are the similarities/differences with prostate cancer? Reflecting on initial results from MRI based screening studies (in Sweden/Germany/UK)	Jeroen Veltman, Hengelo
Prostate cancer screening: What are challenges for MRI implementation?	Anwar Padhani, London
Discussion	

11:55 – 12:50

THE ROLE OF THE GP IN THE PROSTATE CANCER PATHWAY

Philippe Puech, Lille - Marco Blanker, Groningen

What are the challenges for the GP when a patient asks for a PSA-workup? MRI-indication and prescription by GP or urologist? (GP opinion)	Marco Blanker, Groningen
MRI-indication and prescription by urologist or GP? What are criteria for high-quality MRI and where to find? (Radiologist opinion)	Philippe Puech, Lille
How can prostate cancer risk be stratified? MRI-indication and prescription by urologist or GP? (Urologist opinion)	Harm van Melick, Nieuwegein
What are the challenges for the GP, regarding cancer negative men, following urology to GP referral?	Marco Blanker, Groningen
Discussion	

12:50 – 13:00

SUMMARY AND CLOSING

Jelle Barentsz, Nijmegen - Ivo Schoots, Rotterdam

13:05 – 14:00

LUNCH

08:50 – 09:40

PARALLEL SESSION / WORKSHOPS

SESSION 5

ROOM 3: ZOCHERZAAL
HOT 9

Hands-on training (a) (24 people)

Marloes van der Leest, Nijmegen
George Agrotis, LarissaROOM 4: TERSTEEGZAL
HOT 10

Hands-on training (b) (24 people)

Valeria Panebianco, Rome
Margriet van Dijk, AmsterdamROOM 1: COPIJNZAAL
MDT 1CMulti-disciplinary team workshop – MRI and biopsy:
Case-discussion on risk stratification and biopsy
decisionFrancesco Sanguedolce, Barcelona
Jelle Barentsz, Nijmegen
Jolique van Ipenburg, NijmegenROOM 6:
JOHAN DE MEERSTERZAAL
RW 1CRadiological case-based workshop – Prostate MRI:
cases on PI-RADS assessmentVibeke Logager, Copenhagen
Andrea Ponsiglione, NaplesROOM 7: HANS KAZÀNZAAL
RW 2CRadiological case-based workshop – Prostate MRI:
Cases on notorious pitfalls and tricksKai (JC) Vilanova, Girona
Martina Pecoraro, Rome

09:40 – 09:45

CHANGE ROOMS

09:45 – 10:35

PARALLEL SESSION / WORKSHOPS

SESSION 6

ROOM 3: ZOCHERZAAL
HOT 11

Hands-on training (24 people)

Marloes van der Leest, Nijmegen;
Ailin Deghanpour, RomeROOM 4: TERSTEEGZAL
HOT 12

Hands-on training (b) (24 people)

Valeria Panebianco, Rome
Thierry Boellaard, AmsterdamROOM 1: COPIJNZAAL
RW 3CRadiological case-based workshop – MRI quality:
cases on PI-QUAL in daily practiceTristan Barrett, Cambridge
Maarten de Rooij, NijmegenROOM 6:
JOHAN DE MEERSTERZAAL
RW 4CRadiological case-based workshop – MRI challenges:
cases on indeterminate scansGeert Villeirs, Gent
Matthias Roethke, HeidelbergROOM 7: HANS KAZÀNZAAL
RW 7ARadiological case-based workshop – PSMA PET/CT:
cases in high-risk men or indeterminate MRI casesLisa Tarlington, Sydney
Andre Vis, Amsterdam

10:35 – 11:00

COFFEE/TEA BREAK

11:00 – 11:50

PARALLEL SESSION / WORKSHOPS

SESSION 7

ROOM 3: ZOCHERZAAL
HOT 13

Hands-on training (24 people)

Patrik Zamnecik, Nijmegen
Malgorzata Deregowska-Cylke ,ROOM 4: TERSTEEGZAL
HOT 14

Hands-on training (b) (24 people)

Derya Yakar, Groningen
Sam Whitey, BrightonROOM 1: COPIJNZAAL
RW 5CRadiological case-based workshop – MRI in active
surveillance: cases on PRECISE v2.0 assessmentFrancesco Giganti, London
Kai (JC) Vilanova, GironaROOM 6:
JOHAN DE MEERSTERZAAL
RW 6CRadiological case-based workshop – AI / CAD systems
and MRI: Cases on current vendorsTobias Penzkofer, Berlin
Jonathan Richenberg, Brighton
Renato Cuocolo, SalernoROOM 7: HANS KAZÀNZAAL
RW 7CRadiological case-based workshop – PSMA PET/CT:
Cases in high-risk men or indeterminate MRI casesLisa Tarlington, Sydney
Andre Vis, Amsterdam

11:50 – 11:55

CHANGE ROOMS

11:55 – 12:45

PARALLEL SESSION / WORKSHOPS

SESSION 8

ROOM 3: ZOCHERZAAL
HOT 15

Hands-on training (25 people)

Andrea Ponsiglione, Naples
Malgorzata Deregowska-Cylke , WarsawROOM 4: TERSTEEGZAL
HOT 16

Hands-on training (b) (25 people)

Derya Yakar, Groningen
Sam Whitey, BrightonROOM 1: COPIJNZAAL
MDT 2CMultidisciplinary team workshop – Imaging and
staging: cases on T-staging and treatment decision
(surveillance / surgery)Geert Villiers, Gent
Lisa Tarlington, SydneyROOM 6:
JOHAN DE MEERSTERZAAL
MDT 3CMultidisciplinary team workshop – Imaging and
staging: cases on N/M-staging and treatment
decision (surgery/radiation/systemic treatment)Giuseppe Petralia, Milan
Joe Busch, USAROOM 7: HANS KAZÀNZAAL
MDT 4CMultidisciplinary team workshop – Imaging and
radiation: cases on indication, GTV/CTV, and focal
boosting (radiation)Floris Pos, Amsterdam
Patrik Zamecnik, Nijmegen
Harm van Melick, Utrecht
Ulke van der heide, Amsterdam

27TH JUNE THURSDAY

12:40 – 13:40 INDUSTRY LUNCH SYMPOSIUM

Making AI for Prostate MR work in clinical practice

Maarten de Rooij, MD PhD
Radboud University Medical Center
Nijmegen, the Netherlands



*Lunch boxes will be delivered in the Plenary Room

28TH JUNE FRIDAY

13:05 – 14:00 INDUSTRY LUNCH SYMPOSIUM

QP-Prostate®: Unveiling a paradigm shift in prostate cancer management

David Bazaga, Product Lead – Quibim



*Lunch boxes will be delivered in the Plenary Room

28TH JUNE FRIDAY

14:50 – 16:00 AI/CAD SOFTWARE IN PROSTATE CANCER DIAGNOSIS

AI/: WHAT ARE THE CURRENT CE-MARKED AI/CAD TOOLS IN MRI ASSESSMENT?

Representatives: Siemens Healthineers
Lucida Medical
Quibim
Incepto

SPONSORS



courses@esur.org
esur.org

Organising Secretariat

THEORIA
CONGRESOS
Professional Congress Organizer

+34 960 72 82 12
theoriacongresos.com